NCT07152223View on ClinicalTrials.gov

Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 30, 2025

Primary Completion Date

August 31, 2029

Study Completion Date

August 31, 2029

Conditions

Connective Tissue Diseases

Interventions

BIOLOGICAL

CAR-T

Eligible subjects who successfully passed screening will receive CAR-T cell infusion on Day 0 after lymphodepleting preconditioning chemotherapy.

Trial Locations (1)

523125

RECRUITING

Dongguan Taixin Hospital, Dongguan

All Listed Sponsors

lead

Guangzhou Bio-gene Technology Co., Ltd

INDUSTRY

NCT07152223 - Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases | Biotech Hunter | Biotech Hunter